Enzolytics (ENZC) Stock Price, News & Analysis

Company Overview

Enzolytics, Inc. is a biotechnology company dedicated to the discovery and development of novel antiviral therapies and immunotherapeutics. The company leverages a proprietary enzyme-based platform and an intelligent B-cell technology to identify fully human monoclonal antibodies and small-molecule inhibitors targeting a range of viral pathogens. Enzolytics holds an extensive portfolio of patents covering its antiviral compounds and peptide-based drug candidates.

The company’s research and development pipeline includes programs focused on HIV, hepatitis viruses and emerging coronaviruses. Enzolytics applies its enzyme catalysis technology to screen large libraries of compounds for antiviral activity, while its antibody discovery platform enables rapid selection of candidates with high specificity and neutralizing potential. These efforts are aimed at advancing lead molecules through preclinical evaluation toward clinical trials.

Headquartered in West Palm Beach, Florida, Enzolytics conducts collaborative research with academic institutions and contract research organizations across North America and Europe. The company pursues licensing and partnership opportunities to accelerate development and commercialization of its therapeutics. Enzolytics is guided by a management team and board of directors with extensive experience in biotechnology innovation, virology research and pharmaceutical development.

Key Stats

• Today's Range: $0.0006 to $0.0008
• 50-Day Range: N/A
• 52-Week Range: $0.0005 to $0.0043
• Volume: 2.41 million shs
• Average Volume: 4.69 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENZC Stock Analysis - Frequently Asked Questions

How have ENZC shares performed this year?

Enzolytics' stock was trading at $0.0010 at the beginning of the year. Since then, ENZC stock has decreased by 30.0% and is now trading at $0.0007.

How do I buy shares of Enzolytics?

Shares of ENZC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enzolytics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzolytics investors own include HUMBL (HMBL), Bionano Genomics (BNGO), Artificial Intelligence Technology Solutions (AITX), Meta Platforms (META), SNDL (SNDL), Tesla (TSLA).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Entertainment
• Current Symbol: OTCMKTS:ENZC
• CIK: N/A
• Web: enzolytics.com
• Phone: (972) 292-9414
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A